Literature DB >> 9149672

Left ventricular mass in the elderly. The Cardiovascular Health Study.

J M Gardin1, A Arnold, J S Gottdiener, N D Wong, L P Fried, H S Klopfenstein, D H O'Leary, R Tracy, R Kronmal.   

Abstract

Left ventricular (LV) mass, as estimated from M-mode echocardiography (echo), has previously been shown to be an independent predictor of incident cardiovascular disease morbidity and mortality. We evaluated the relationship at baseline of echo LV mass to relevant cardiovascular disease risk factors and other potential covariates in the Cardiovascular Health Study, multicenter study sponsored by the National Heart, Lung, and Blood Institute of 5201 men and women aged 65 years or older (mean, 73). Two-dimensionally directed M-mode echo LV mass measurements could be obtained in 1357 men and 2053 women (66% of this elderly cohort). Stepwise linear regression analyses of the relationship of echo LV mass to demographic and risk factor, physical activity, electrocardiographic, and prevalent disease variables resulted in a model that explained 37% of the variance for the entire cohort. In order of decreasing importance, factors positively associated with echo LV mass were body weight, male sex, systolic pressure, presence of congestive heart failure, present smoking, major and minor electrocardiographic abnormalities, treatment for hypertension, valvular heart disease, aortic regurgitation by color Doppler, and mitral regurgitation by color Doppler (in men) whereas diastolic pressure, bioresistance (a measure of adiposity), and high-density lipoprotein cholesterol were inversely related to echo LV mass. Although height and weight were both related to LV mass, height added nothing once weight was entered in multiple linear regression analyses. Furthermore, in the multiple regression models, diastolic pressure was inversely and systolic BP positively related to LV mass, with similar magnitudes for their coefficients. In consonance with these findings, pulse pressure was positively related to LV mass in bivariate analyses. Multiple linear regression analyses explained less of the variance for ventricular septal thickness (R2 = .13) and LV posterior wall thickness (R2 = .14) than for LV mass (R2 = .37) and LV diastolic dimension (R2 = .27). Intriguing findings in the elderly Cardiovascular Health Study cohort included the presence of pulse pressure as a positive correlate, and high-density lipoprotein cholesterol as an inverse correlate, of LV mass. Longitudinal studies in the Cardiovascular Health Study cohort will help to clarify the importance of demographic, risk factor, and other variables, and changes in these variables, in predicting changes in echo LV mass and its components as well as the prognostic significance of LV mass in the elderly.

Entities:  

Mesh:

Year:  1997        PMID: 9149672     DOI: 10.1161/01.hyp.29.5.1095

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  34 in total

Review 1.  Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

Authors:  S S Franklin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 2.  Epidemiology of risk factors for hypertension: implications for prevention and therapy.

Authors:  M Kornitzer; M Dramaix; G De Backer
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

3.  Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance.

Authors:  Julio A Chirinos; Patrick Segers; Marc L De Buyzere; Richard A Kronmal; Muhammad W Raja; Dirk De Bacquer; Tom Claessens; Thierry C Gillebert; Martin St John-Sutton; Ernst R Rietzschel
Journal:  Hypertension       Date:  2010-05-10       Impact factor: 10.190

Review 4.  Cardiac remodeling at the population level--risk factors, screening, and outcomes.

Authors:  Ola Gjesdal; David A Bluemke; Joao A Lima
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

5.  Is pulse pressure an independent risk factor for incident acute coronary heart disease events? The REGARDS study.

Authors:  Stephen P Glasser; Daniel L Halberg; Charlie Sands; Christopher M Gamboa; Paul Muntner; Monika Safford
Journal:  Am J Hypertens       Date:  2013-09-12       Impact factor: 2.689

6.  Changes in arterial stiffness following dialysis in relation to overhydration and to endothelial function.

Authors:  Simona Hogas; Serban Ardeleanu; Liviu Segall; Dragomir Nicolae Serban; Ionela Lacramioara Serban; Mihai Hogas; Mugurel Apetrii; Mihai Onofriescu; Radu Sascau; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-03-19       Impact factor: 2.370

7.  Relation of pulse pressure to blood pressure response to exercise in patients with hypertrophic cardiomyopathy.

Authors:  Kevin S Heffernan; Martin S Maron; Eshan A Patvardhan; Richard H Karas; Jeffrey T Kuvin
Journal:  Am J Cardiol       Date:  2010-12-22       Impact factor: 2.778

8.  The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide.

Authors:  S Jeson Sangaralingham; Brenda K Huntley; Fernando L Martin; Paul M McKie; Diego Bellavia; Tomoko Ichiki; Gerald E Harders; Horng H Chen; John C Burnett
Journal:  Hypertension       Date:  2010-12-28       Impact factor: 10.190

9.  Gender, race, age, and regional differences in the association of pulse pressure with atrial fibrillation: the Reasons for Geographic and Racial Differences in Stroke study.

Authors:  Lama Ghazi; Monika M Safford; Yulia Khodneva; Wesley T O'Neal; Elsayed Z Soliman; Stephen P Glasser
Journal:  J Am Soc Hypertens       Date:  2016-06-07

10.  Smoking and Cardiac Structure and Function in the Elderly: The ARIC Study (Atherosclerosis Risk in Communities).

Authors:  Wilson Nadruz; Brian Claggett; Alexandra Gonçalves; Gabriela Querejeta-Roca; Miguel M Fernandes-Silva; Amil M Shah; Susan Cheng; Hirofumi Tanaka; Gerardo Heiss; Dalane W Kitzman; Scott D Solomon
Journal:  Circ Cardiovasc Imaging       Date:  2016-09       Impact factor: 7.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.